RxDoctor Payments Data

Ahmad Hadid, MD

Cardiovascular Disease · New Windsor, NYNPI 1558364414

Payments from drug & device makers

$1,837in general payments, 2019–2025

Across 32 payments — averaging $57.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$546
  • Boston Scientific$297
  • Amgen$250
  • Novartis$174
  • Abbott$159
  • Medtronic$123
  • plus $288 from 7 others

What the payments were for

  • Grants$17810%
  • Food & beverage$1,65990%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,837 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$325,937
Medicare patients
738
Services billed
2,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$193,343
EntrestoSacubitril/Valsartan41$64,271
BrilintaTicagrelor33$36,994
FarxigaDapagliflozin Propanediol22$30,708
XareltoRivaroxaban17$26,817
Metoprolol Succinate392$7,542
Atorvastatin Calcium356$4,347
Clonidine14$3,455
ClopidogrelClopidogrel Bisulfate260$3,266
Rosuvastatin Calcium190$2,912
Losartan Potassium239$2,572
Carvedilol220$2,367
Levothyroxine Sodium83$1,977
Valsartan42$1,462
Amlodipine Besylate240$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$193,343142 claims
AstraZenecaBrilinta, Farxiga$546$67,70255 claims
NovartisEntresto$174$64,27141 claims
Johnson & JohnsonXarelto$66$26,81717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →